Split ch2 domains

Patent metadata

Field	Value
Publication number	US-2023103563-A1
Application number	US-202117908190-A
Country	US
Kind code	A1
Filing date	Mar 29, 2021
Priority date	Mar 30, 2020
Publication date	Apr 6, 2023
Grant date	—

Abstract

The invention relates to a protein complex comprising at least two polypeptide chains A (PCA) and B (PCB), wherein PCA comprises a heterodimerization domain A (HDA) and PCB comprises a heterodimerization domain B (HDB), wherein HDA and HDB bind to each other and wherein one heterodimerization domain comprises or consists of two N-terminal β-strands (N-β) of an immunoglobulin (Ig) domain and the other heterodimerization domain comprises or consists of two C-terminal β-strands (C-β) of an Ig domain. The invention further relates to polynucleotides encoding one or more polypeptides of the protein complex, expression vectors comprising the polynucleotides and a cell comprising the polynucleotides or the expression vectors.

First claim

1 . A protein complex comprising at least two polypeptide chains A (PCA) and B (PCB), wherein PCA comprises a heterodimerization domain A (HDA) and PCB comprises a heterodimerization domain B (HDB) that bind to each other and wherein one heterodimerization domain comprises or consists of two N-terminal ß-strands of an immunoglobulin (Ig) domain (N-ß) and the other heterodimerization domain comprises or consists of two C-terminal ß-strands of an Ig domain (C-ß).

2 . The protein complex according to claim 1 , wherein
a. N-ß comprises a continuous amino acid sequence of an Ig domain comprising at least ß-strand b and c and b. C-ß comprises a continuous amino acid sequence of an Ig domain comprising at least ß-strand e and f.

3 . The protein complex according to claim 1 or 2 , wherein the Ig domains of N-ß and C-ß are independently selected from an IgA, IgD, IgE, IgG, IgG1, IgG2, IgG3, or IgG4 heavy chain constant domain 2 (CH2), and an IgM or IgE heavy chain constant domain 3 (CH3), and are optionally selected from the same CH2 or CH3.

4 . The protein complex according to claim 1 , wherein HDA and HDB (i) non-covalently or (ii) non-covalently and covalently bind to each other.

5 . The protein complex according to claim 3 , wherein N-ß comprises or consists of a continuous amino acid sequence of a CH2 or CH3 domain comprising or consisting of ß-strand a to ß-strand c and C-ß comprises or consists of a continuous amino acid sequence of a CH2 or CH3 domain comprising or consisting of ß-strand e to ß-strand g.

6 . The protein complex according to claim 1 , wherein the N-ß and C-ß each comprise a non-naturally occurring Cys residue and wherein the Cys residues replace amino acids in the folded N-ß and C-ß, respectively, that naturally have a distance of between 3 to 7.5 Å between their Cα-atoms.

7 . The protein complex according to claim 1 , wherein HDA comprises or consists of:
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSX 1 EDPEVX 2 FX 3 WYVDGVEVHN (SEQ ID NO: 1), wherein X 1 is H or Q, X 2 is K or Q and X 3 is N or K; or a variant thereof with an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% identity to SEQ ID NO: 1; and/or HDB comprises or consists of: NSTX 4 RVVSVLTVX 5 HQDWLNGKEYKCKVSNKX 6 LPX 7 X 8 IEKTI (SEQ ID NO: 2), wherein X 4 is Y or F; X 5 is L or V; X 6 is A or G; X 7 is K or Q; X 8 is N or K; or a variant thereof with an amino acid sequence with at least 80%, 85%, 90%, 95%, 96%, 97%, 98% identity to SEQ ID NO: 2, wherein SEQ ID NO: 1 or its variant can heterodimerize with SEQ ID NO: 2 or its variant.

8 . The protein complex according to claim 1 , wherein the complex comprises one or more antigen binding sites within the PCA and/or the PCB, wherein each of the one or more antigen binding sites is formed by a pair of two domains, wherein one is comprised in the PCA and the other is comprised in the PCB, and wherein the antigen binding site(s) are located N- and/or C-terminally of the HDA or HDB.

9 . The protein complex according to claim 1 , wherein the PCA and/or the PCB comprises one or more further homo and/or heterodimerization domain C (HDC), wherein the homodimerization domain is selected from the group consisting of a CH3 domain, a CH2-CH3 domain, or a domain where homodimerization is mediated by a an Ig-like fold, a rossmann- or rossmann-like alpha-beta-alpha sandwich fold, an alpha-sandwich fold, a continuous-beta-sheet fold, a beta-sandwich fold, a mixed beta-sheet fold, a 2-helix orientation, an antiparallel alpha-helix-orientation, a parallel alpha-helix orientation, a 4-helix bundle motif, a leucine zipper and a coiled-coil domain and the heterodimerization domain is selected from the group consisting of a knob-into-hole CH3 domain, a knob-into-hole CH2-CH3 domain, a Fc-domain with introduced mutations to force heterodimerization (e.g. charged mutations), a domain of a pair of interchanged domains (such as Fc-one/kappa heterodimerization domain, CL and CH domains), an Ig-like fold with introduced mutations to force heterodimerization, or a domain mediating heterodimerization containing a rossmann- or rossmann-like alpha-beta-alpha sandwich fold, an alpha-sandwich fold, a continuous-beta-sheet fold, a beta-sandwich fold, a mixed beta-sheet fold, a 2-helix orientation, an antiparallel alpha-helix-orientation, a parallel alpha-helix orientation, a 4-helix bundle motif, a leucine zipper and a coiled-coil domain; wherein the antigen binding site(s) are located N- and/or C-terminally of the HDC.

10 . The protein complex according to claim 8 , wherein PCA and PCB comprise from N- to C-terminus the following elements:
(i) PCA: V2-L1-HDA, and PCB: V2-L2-HDB; (ii) PCA: V1-L3-HDA-L4-V2, and PCB: V1-L1-HDB-L2-V2; (iii) PCA: V1-L1-V2-L2-HDA, and PCB: V2-L3-V1-L4-HDB; (iv) PCA: V1-L3-V2-L5-CL-L4-HDA, and PCB: V1-L1-V2-L6-CH1-L2-HDB; wherein L5, CL, L6 and CH1 may be present or absent; or (v) PCA: V1-L4-V2-L5-CL-L6-HDA, and PCB: V2-L1-V1-L2-CH1-L3-HDB; wherein L5, CL, L2 and CH1 may be present or absent; wherein each pair of V1, V2, V3, and V4 comprises a variable domain of a heavy chain and a variable domain of a light chain or a variable domain of an alpha chain and a variable domain of a beta chain and forms an antigen binding site, wherein L1 to L6 are peptide linkers, and wherein the PCA and/or the PCB optionally further comprises a HDC.

11 . The protein complex according to claim 10 , wherein the PCA and/or the PCB comprises a first HDC, and wherein the complex comprises one or more additional polypeptides comprising one or more antigen binding sites and a second HDC that is covalently or non-covalently bound to the first HDC.

12 . One or more polynucleotides encoding one or more polypeptides of the protein complex according to claim 1 .

13 . One or more expression vectors comprising the one or more polynucleotides according to claim 12 .

14 . A cell comprising the one or more polynucleotides of claim 12 or one or more expression vectors comprising said one or more polynucleotides.

15 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the protein complex according to claim 1 , the one or more polynucleotides encoding one or more polypeptides of said protein complex, or one or more expression vectors comprising said one or more polynucleotides.

Assignees

• Sanofi Sa

Inventors

• Dittrich Werner
• Focken Ingo
• Lange Christian
• Langer Thomas
• Rao Ercole

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C07K16/247 Primary

  IL-4 · CPC title

• C07K2317/524

  CH2 domain · CPC title

• C07K2317/626

  Diabody or triabody · CPC title

• C07K16/244

  Interleukins [IL] · CPC title